HCA Healthcare vs Surgery Partners
HCA and SGRY side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HCA and SGRY compare
HCA Healthcare is the larger company, worth 30 times as much as Surgery Partners ($104B against $3.5B).
HCA Healthcare grew revenue faster over the last twelve months (5.8% versus 2.2% for Surgery Partners).
HCA Healthcare keeps more of each dollar of sales as profit, with a net margin of 8.6% compared with −2.6% at Surgery Partners.
HCA Healthcare pays a dividend yielding 0.61%; Surgery Partners does not pay one.
HCA Healthcare scores higher on the StockData Score (9 against 5 for Surgery Partners), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HCA | SGRY |
|---|---|---|
| Size and price | ||
| Market cap | $104B | $3.5B |
| Share price | $499.05 | $26.95 |
| Change, 1 year | 5.4% | 69.9% |
| Change, 5 years | 109% | −44.3% |
| Beta (5Y) | 0.73 | 1.58 |
| Employees | 320K | 16K |
| StockData Score | ||
| Total score | 9 (better) | 5 |
| Valuation score | 1 | 2 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 2 (better) | 1 |
| Health score | 1 | 2 (better) |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 16.5× | – |
| P/S | 1.3× | 1.1× (better) |
| P/B | – | 2.1× |
| EV/EBITDA | 9.9× (better) | 13.8× |
| P/FCF | 17.5× | 17.4× (better) |
| PEG | 1.19 | – |
| FCF yield | 5.7% | 5.7% (better) |
| Fair value | $492.25 | $25.00 |
| Margin of safety | −1.4% (better) | −7.8% |
| Growth | ||
| Revenue growth (TTM) | 5.8% (better) | 2.2% |
| Revenue growth, 5Y average | 8.0% | 12.2% (better) |
| Net income growth (TTM) | 6.8% | – |
| EPS growth (TTM) | 16.7% | – |
| EPS growth, 5Y average | 21.0% | – |
| Profitability | ||
| Operating margin | – | 10.8% |
| Net margin | 8.6% (better) | −2.6% |
| FCF margin | 7.6% (better) | 6.0% |
| Return on equity | – | −5.1% |
| Return on invested capital | – | 6.1% |
| Financial health | ||
| Debt / equity | – | 1.84 |
| Net debt / EBITDA | 3.11 (better) | 4.99 |
| Current ratio | 0.82 | 2.17 (better) |
| Altman Z-score | 1.92 (better) | 1.08 |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Dividend yield | 0.61% | – |
| Payout ratio | 10.1% | – |
| Years of dividend growth | 5 | – |
| Dividend growth, 5Y average | 46.3% | – |
| Buyback yield | 8.8% | – |
| Shareholder yield | 9.4% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 64.4% | 121% |
| Held by insiders | 46.0% | 85.9% |
| Insider net buying, 12 months | −$47.5M | −$979K (better) |
| Superinvestors holding | 3 (better) | 1 |
| Short interest, % of float | 4.3% | 48.6% |
Go deeper
- HCA stock overview
- HCA income statement
- HCA valuation and score
- SGRY stock overview
- SGRY income statement
- SGRY valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.